secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2021-07-19T23:59:59+00:00
Accession:  0001193125-21-218690
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics appoints Martin Babler as Class II director, effective July 19, 2021
--------------------------------------------------------------------------------

- Martin Babler appointed to Board as Class II director and Audit Committee member, effective July 19, 2021.
- Babler previously President and CEO of Principia Biopharma until its acquisition by Sanofi in October 2020.
- Received non-incentive stock options for 36,400 shares vesting monthly over three years under 2020 Equity Incentive Plan.
- Will receive standard non-employee director compensation and enter into customary indemnity agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312521218690/0001193125-21-218690-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312521218690/d172272d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-218690

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer